Eleftherios P Mamounas MD
Breast, Surgical Oncology (Other than Breast)
Professor of Surgery, Northeast Ohio Medical University
Join to View Full Profile
2501 N Orange AveSte 389Orlando, FL 32804
Phone+1 407-303-5214
Fax+1 407-909-6944
Dr. Mamounas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UPMC Medical Education (Pittsburgh)Residency, Surgery, 1984 - 1989
University of AthensClass of 1983
Certifications & Licensure
FL State Medical License 2012 - 2027
OH State Medical License 1997 - 2014
PA State Medical License 1985 - 1998
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Fluorescence Imaging of Carcinoma During Breast Conserving Surgery Start of enrollment: 2021 Apr 27
Roles: Principal Investigator
Publications & Presentations
PubMed
- Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations.Mariem Galuia, Julia Fedorova, Wassim McHayleh, Eleftherios Mamounas, Sarfraz Ahmad
Current Oncology. 2025-03-09 - 3 citationsSurvival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.Charles E Geyer Jr, Michael Untch, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas
The New England Journal of Medicine. 2025-01-16 - 1 citationsQuality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.Patricia A Ganz, Reena S Cecchini, Julia R White, Frank A Vicini, Douglas W Arthur
Journal of the National Cancer Institute. 2025-01-01
Journal Articles
- 21-Gene Assay as Predictor of Chemotherapy Benefit in HER2-Negative Breast CancerEleftherios P Mamounas, Frederick L Baehner, Norman Wolmark, D Lawrence Wickerham, Nature
- Clinical Relevance of the 21-Gene Recurrence Score® Assay in Treatment Decisions for Patients with Node-Positive Breast Cancer in the Genomic EraEleftherios Mamounas, MD, Nature
Lectures
- NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to ...2019 ASCO Annual Meeting - 6/1/2019
- NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
21-Gene Recurrence Score for Prognosis and Prediction of Taxane Benefit After Adjuvant Chemotherapy plus Endocrine Therapy: Results from NSABP B-28/NRG OncologyNovember 11th, 2019
Do Trials Results Conflict for Extended AI in Breast Cancer?December 8th, 2016
Conversations with Oncology Investigators Bridging the Gap Between Research and Patient CareDecember 26th, 2007- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
